---
title: What Is Presbyopia? | Orasis Pharmaceuticals
description: Presbyopia is the gradual, age-related loss of near focus, typically beginning after age 40 and affecting more than 1.8 billion people worldwide.
image: https://orasis-pharma.com/hubfs/raw_assets/public/orasis-website/images/home-hero-bg.jpg
---
[Skip to content](https://orasis-pharma.com/presbyopia#main-content)
[ ](https://orasis-pharma.com?hsLang=en)
- [ About ](https://orasis-pharma.com/about?hsLang=en)
#### [Company Overview Our mission, vision, and story](https://orasis-pharma.com/about?hsLang=en)
#### [Leadership Team Meet the executives driving our vision](https://orasis-pharma.com/leadership?hsLang=en)
#### [Board of Directors Guidance from industry leaders](https://orasis-pharma.com/board?hsLang=en)
#### [Investors Our partners in innovation](https://orasis-pharma.com/investors?hsLang=en)
- [ Qlosi ](https://orasis-pharma.com/qlosi?hsLang=en)
- [ Presbyopia ](https://orasis-pharma.com/presbyopia?hsLang=en)
- News
[Press Releases](https://orasis-pharma.com/press-releases?hsLang=en) [In the Media](https://orasis-pharma.com/in-the-media?hsLang=en)
- [Contact](https://orasis-pharma.com/contact?hsLang=en)
[Qlosi.com](https://qlosi.com?hsLang=en)
The Condition
# Understanding Presbyopia
The Condition
## What Is Presbyopia?
Presbyopia is the gradual loss of your eye’s ability to focus on near objects as a result of the natural aging process. This progressive condition begins to affect most people after the age of 40 when the crystalline lens of the eye gradually stiffens and loses flexibility, resulting in the inability to focus on near objects. There are more than 1.8 billion people globally, and more than 116 million people in the U.S., living with presbyopia.
People with presbyopia experience blurred vision when performing daily tasks that require near visual acuity, such as reading a book, a restaurant menu or messages on a smartphone. Presbyopia cannot be prevented or reversed, and many existing treatment options can be either cumbersome or invasive, presenting a significant unmet need for quality-of-life improvement.
By the Numbers
## Presbyopia by the Numbers
>1.8B
People Affected Globally
116M
Americans With Presbyopia
40+
Age When Symptoms Typically Begin
## Get in Touch
Ready to see what's possible? Contact us here.
[Contact Us](https://orasis-pharma.com/contact?hsLang=en)
[ ](https://orasis-pharma.com/?hsLang=en)
An ophthalmic pharmaceutical company delivering solutions to reshape vision possibilities.
#### Company
[Company Overview](https://orasis-pharma.com/about?hsLang=en) [Leadership Team](https://orasis-pharma.com/leadership?hsLang=en) [Board of Directors](https://orasis-pharma.com/board?hsLang=en) [Investors](https://orasis-pharma.com/investors?hsLang=en)
#### Product
[About Qlosi](https://orasis-pharma.com/qlosi?hsLang=en) [About Presbyopia](https://orasis-pharma.com/presbyopia?hsLang=en) [Qlosi.com](https://qlosi.com?hsLang=en)
#### News & Contact
[Press Releases](https://orasis-pharma.com/press-releases?hsLang=en) [In the Media](https://orasis-pharma.com/in-the-media?hsLang=en) [Contact Us](https://orasis-pharma.com/contact?hsLang=en) [info@orasis-pharma.com](mailto:info@orasis-pharma.com)
©2026 Orasis Pharmaceuticals, Inc. All Rights Reserved. QLOSI®, Orasis Pharmaceuticals, the Orasis Pharmaceuticals logo, and certain other trademarks herein are trademarks of Orasis Pharmaceuticals, Inc.
[Privacy Policy](https://orasis-pharma.com/privacy-policy?hsLang=en) [Terms of Service](https://orasis-pharma.com/terms-of-service?hsLang=en) [Health Data Privacy](https://orasis-pharma.com/health-data-privacy-policy?hsLang=en)
```json
{
"@context" : "https://schema.org",
"@id" : "https://www.orasis-pharma.com/#organization",
"@type" : "Organization",
"address" : {
"@type" : "PostalAddress",
"addressCountry" : "US",
"addressLocality" : "Ponte Vedra",
"addressRegion" : "FL",
"postalCode" : "32081",
"streetAddress" : "203 Fort Wade Rd., #140"
},
"contactPoint" : {
"@type" : "ContactPoint",
"contactType" : "customer service",
"email" : "info@orasis-pharma.com",
"telephone" : "+1-866-672-7471"
},
"description" : "Orasis Pharmaceuticals is an ophthalmic pharmaceutical company delivering solutions to reshape vision possibilities, developer of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults.",
"logo" : "https://qlosiecp.com/hubfs/HQ%20Only/Orasis_Pharmaceuticals_Logo_RGB.svg",
"name" : "Orasis Pharmaceuticals",
"sameAs" : [ "https://www.linkedin.com/company/orasis-pharmaceuticals/", "https://twitter.com/OrasisPharma" ],
"url" : "https://www.orasis-pharma.com/"
}
```
```json
{
"@context" : "https://schema.org",
"@id" : "https://www.orasis-pharma.com/#website",
"@type" : "WebSite",
"name" : "Orasis Pharmaceuticals",
"publisher" : {
"@id" : "https://www.orasis-pharma.com/#organization"
},
"url" : "https://www.orasis-pharma.com/"
}
```